AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Beyond BMI criteria, ideal candidates are patients who have attempted lifestyle modifications (diet, exercise) without achieving adequate or sustained weight loss
Due to the need for once-daily injections with liraglutide and the decreased effectiveness compared to semaglutide we have opted not to offer liraglutide at this time
We do not need to wait until CKM is available, although it could provide additional safety. Self-advocacy is key to success with adjunctive therapies As with all aspects of diabetes, its important to self-advocate for your care and prove to your healthcare provider that you are a good candidate for an off-label therapy because you have done your research
Months 1224: Consolidation & Habit Building By 12 months, most patients are near their maximum semaglutide-assisted weight loss
Zepbound and Mounjaro prescribing information also describe delayed gastric emptying with tirzepatide